Mirati to begin clinical trials of treatment for KRASG12D colorectal cancer
The U.S. Food and Drug Administration (FDA) has cleared the way for Mirati Therapeutics to begin clinical trials of MRTX1133, a potential first-in-class oral treatment for patients with the KRASG12D colorectal cancer mutation.
About 180,000 colorectal cancer patients in the U.S. and Europe are affected by this mutation, and no targeted oncology treatment options currently exist for them, according to a press release from Mirati.
MRTX1133, an inhibitor of KRASG12D, has shown marked tumor response in preclinical colorectal cancer models, according to the company, as well as a low risk for off-target activity and unwanted drug interactions.
"This particular mutation has been difficult to target, and we are confident in our novel oral formulation strategy, which we believe will enable near-complete target inhibition over the full dosing interval," said James Christensen, Ph.D., and chief scientific officer at Mirati. "We are thrilled to advance MRTX1133 into clinical development and the potential to positively impact people living with KRASG12D-mutated cancers."
The therapy has also shown promise in pancreatic and lung cancer models.
The Phase 1/2 clinical trial will launch in early 2023 with plans for multiple expansion cohorts in pancreatic, colorectal, lung and other KRASG12D tumor types.
For more information, view Mirati’s press release or visit Mirati.com/science.
Top resources
FDA approves immunotherapy for MSI-H/dMMR stage II & III rectal cancer
The U.S. Food and Drug Administration approved dostarlimab (brand name Jemperli) as the first and only immunotherapy for adults with stage II or III rectal cancer that has a biomarker called MSI-H or dMMR.
FDA approves Tecentriq for some people with stage III colon cancer
The FDA has approved Tecentriq (atezolizumab), given with chemotherapy after surgery, for people with stage III colon cancer whose tumors are mismatch repair deficient (dMMR). It’s the first immunotherapy approved for this use.
A blood test that sees what scans can't
For many cancer patients, the end of active treatment brings a new kind of dread. Scans every few months and anxious waits for results. A blood test is changing that experience for a growing number of patients.